droe-NAB-i-nol 
Absorption: Extensively metabolized following absorption, resulting in poor bioavailability (10–20%).
Distribution: Enters breast milk in high concentrations. Highly lipid-soluble. Persists in tissues for prolonged period of time.
Protein Binding: 97%.
Metabolism/Excretion: Mostly metabolized by the hepatic CYP2C9 isoenzyme (CYP3A4 also involved); the CYP2C9 enzyme system exhibits genetic polymorphism; poor metabolizers may have significantly ↑ dronabinol concentrations and an ↑ risk of adverse effects; 50% excreted via biliary elimination. At least one metabolite is psychoactive.
Half-life: 25–36 hr.
Contraindicated in:
Use Cautiously in:
CV: hypertension, hypotension, palpitations, syncope, tachycardia.
Derm: facial flushing.
EENT: dry mouth.
GI: abdominal pain, nausea, vomiting.
Neuro: ataxia, paresthesia , SEIZURES, anxiety, concentration difficulty, confusion, dizziness, drowsiness, mood change, abnormal thinking, amnesia, depression, disorientation, euphoria, hallucinations, headache, impaired judgment, paranoia.
Misc: physical dependence, psychological dependence (high doses or prolonged therapy).
Drug-Drug:
Drug-Natural Products:
Drug-Food:
Nausea and Vomiting Associated with Cancer Chemotherapy
Anorexia Associated with Weight Loss in AIDS
14 French (nasogastric tube [NG tube], gastrostomy tube [G-tube], percutaneous endoscopic gastrostomy tube [PEG-tube] and gastrojejunostomy tube [GJ-tube]. Do not use polyurethane tubes. Flush feeding tube with 30 mL of water.
Schedule II (C-II)(oral solution)
Schedule III (C-III)(capsules)
(Generic available)
NDC Code*